ClinicalTrials.gg
CompletedNCT02183220Updated Jul 8, 2014

Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache

A Phase 3 interventional study of Metamizol and Acetylsalicylic acid (ASA) in Migraine Disorders, sponsored by Boehringer Ingelheim. Completed. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-07-08.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
417
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

The objective of the study was to evaluate the efficacy, safety and tolerability of a single peroral dose of 0.5 g and 1.0 g metamizol relative to placebo and 1.0 g acetylsalicylic acid in 2 episodes of moderate tension headache.

02

Conditions studied

  • Migraine Disorders

Browse trials for

03

In context

Migraine Disorders

1,658 studies on the registry are indexed under Migraine Disorders; 340 are open to participants now.

This study's enrollment of 417 is above the median of 80 across 1,269 interventional studies indexed under Migraine Disorders.

Browse Migraine Disorders studies →

Lead sponsor

Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.

Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients between 18 and 65 years old
  • Moderate episodic tension headache according to International Headache Society (I.H.S.) classification 2.1 (2.1.1 and 2.1.2) for at least one year
  • At least two episodes of tension headache per month in the last three months prior to enrolment into this trial
  • The episodes of tension headaches were usually treated by the patient successfully with a non-opioid-analgesic
  • First episodic headache occurred at an age under 50 years
  • Written according to Good Clinical Practice (GCP) and local regulations
  • The patient was able to fill in the Patient's Diary

Exclusion criteria

Exclusion Criteria:

  • The patient usually needs for successful treatment of tension headache "Over The Counter" (OTC) analgesic in doses exceeding the doses tested here
  • The patient takes an OTC-analgesic normally at the first signs of an episode of tension headache
  • The patient has more than 15 episodes of tension headache per month
  • Female patients whose episodic tension headache is strongly correlated with the start of hormonal
  • Concomitant treatment with (non-) prescriptional analgesics
  • Pre- (less than 4 weeks prior to inclusion in this trial) and/or concomitant treatment with an antidepressive and/or antipsychotic drug
  • Pre- (less than 2 weeks prior to inclusion in this trial) and/or concomitant treatment with any drug such as NSAIDs (Non-Steroidal Anti Inflammatory Drugs), propanolol, metroprolol, flunarizin, cyclandelate, valproic-acid, serotonergic antagonists, ergotamine, dihydroergotamines and benzodiazepines that may influence the headache symptomatology
  • Use of benzodiazepines in the previous 24 hours to the administration of the study drug. Occasional use of benzodiazepines - up to 3 per week - is allowed
  • Use of any drug with analgesic properties in the previous 24 hours to the administration of the study drug
  • Concomitant treatment with any drug containing ASA and/or metamizol
  • Concomitant treatment with anticoagulants such as heparin or coumarin-derivatives
  • Alcohol and drug abuse according to (Diagnostic and Statistical Manual of Mental Disorders )
  • Female patients in child-bearing age not using adequate means of birth control
  • Pregnancy and/or lactation
  • Gastrointestinal ulcers
  • Liver and/or renal disease
  • Bronchial asthma
  • Relevant allergy or known to the drugs, its and/or to other NSAIDs
  • Participation in another clinical trial within the last 4 weeks and concurrent participation in another clinical trial
  • Patients with active gastroesophageal flux disease (Amendment number 1)
  • Concomitant treatment with analgesics or any other drug that may have influenced the headache symptomatology - including metamizol or ASA -, was referred to its use during the headache episodes under evaluation. As long as appropriate were respected, analgesics were allowed in between the episodes of tension headache (TH) and their use as a rescue medication did not lead to the exclusion of the patient (Amendment number 2)
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
417 participants (actual)

Study arms

  • Experimental
    Metamizol high & Placebo

    Drug: Metamizol · Drug: Metamizol placebo

  • Experimental
    Metamizol low & Placebo

    Drug: Metamizol · Drug: Metamizol placebo

  • Active comparator
    Acetylsalicylic acid & Placebo

    Drug: Acetylsalicylic acid (ASA) · Drug: ASA placebo

  • Placebo comparator
    Placebo

    Drug: Metamizol placebo · Drug: ASA placebo

Interventions

06

What researchers measure

Primary outcomes

  1. Time-interval weighted sum of pain intensity difference (SPID) on a Visual Analogue Scale (VAS)

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

Secondary outcomes

  1. Pain intensity difference (PID) on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  2. Maximum pain intensity difference (MAXPID) on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  3. Number of patients with at least a 50% pain reduction on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  4. Time to 50% pain intensity reduction on a VAS

    Time frame: before and 30 minutes, 1, 2, 3, and 4 hours after drug intake

  5. Maximum pain relief (MAXPAR) on a Verbal Rating Scale (VRS)

    Time frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake

  6. Total pain relief (TOTPAR) on a VRS

    Time frame: 30 minutes, 1, 2, 3, and 4 hours after drug intake

  7. Number of patients using rescue medication

    Time frame: 2, 3, and 4 hours after drug intake

  8. Global efficacy assessment on a VRS by the patient and investigator

    Time frame: 4 hours after drug intake

  9. Number of patients with adverse events

    Time frame: up to 2 months

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 1998 and a primary completion of Jul 1999. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 4, 2014
First posted
Jul 8, 2014
Start
Oct 1998
Primary completionActual
Jul 1999
Last update
Jul 8, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 8, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02183220
Responsible party
Sponsor
First posted
Jul 8, 2014
Start date
Oct 1998
Primary completion
Jul 1999
Last update
Jul 8, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dipyrone

Start the discussion